Cardiometabolic Diseases Market—Trends and Growth Opportunities, Forecast to 2022

Cardiometabolic Diseases Market—Trends and Growth Opportunities, Forecast to 2022

Shift Towards a 'Comprehensive Care Continuum' with the Adoption of Integrated Care Pathways that Combine Clinical Therapies with Wellness Programs

RELEASE DATE
06-Jun-2018
REGION
Global
Research Code: MDB6-01-00-00-00
SKU: HC03018-NA-MR_21980

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03018-NA-MR_21980

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Globally, cardiometabolic diseases are witnessing a consistent rise in prevalence every year, with hypertension and diabetes among the leading conditions. A rising population of hypertension is, in turn, leading to growing incidence of chronic heart failure with about 26 million cases of CHF globally. Although drug therapies are the first line of treatment in cases of CHF, hypertension, and diabetes, obesity treatment requires a mixture of nutritional, behavioral, and drug therapies, wherein drugs act as an adjunct to the behavioral therapies.

With the growing number of cardiometabolic cases worldwide, the market is slowly shifting toward ‘Therapy-as-a-Service’ model, with the implementation of adjunct therapies such as digital therapeutics, AI-based predictive diagnostic tools as well as nutritional and behavioral therapies alongside traditional drug treatment. This has helped establish a comprehensive care continuum across the industry, with wellness programs playing an important role in disease diagnosis, treatment, and monitoring.

Research Scope

The present study aims at identifying some of the key growth opportunities, which are set to drive the market in the next few years. Additionally, the study also identifies the most prevalent and emerging business models across the market, which are supporting industry stakeholders in enhancing their geographic coverage in terms of patient outreach and address challenges of inadequate patient access. The study provides in-depth revenue and market analysis of 4 key markets, chronic heart failure (CHF), hypertension, diabetes, and obesity. The study also highlights some of the key market drivers and restraints that affect the growth. It gives an overview of the competitive environment providing brief insights on some of the game-changing participants across each segment that are working toward developing disruptive technologies and drugs, thus maintaining their growth trajectory. Focus is also given on some of the leading M&A activities impacting the market as well as present and future market trends that would shape the market.


Key Issues Addressed

  • How is the market attractiveness for cardiometabolic therapeutics evolving over the years? What is the future market potential?
  • What is the role played by primary and community care in management of cardiometabolic diseases?
  • What are the current and future trends impacting the market growth? What are the emerging business models set to transform the market landscape?
  • What are the key regulatory and pricing changes across the cardiometabolic market? How are these changes expected to affect the market in the long run?
  • What are the major growth opportunities across the cardiometabolic diseases market? What kind of impact would these have on the market growth?
  • What are the applications of emerging technologies and digital transformation on the overall market? How is it expected to impact the market in the next few years?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings

Key Findings (continued)

Scope and Segmentation

Key Questions to be Answered

Market Engineering Measurements

Market Engineering Measurements (continued)

Market Engineering Measurements (continued)

Market Engineering Measurements (continued)

CEO’s Perspective

Big Market Themes

Executive Summary—3 Big Predictions

Market Segmentation

Key Trends and Impact on the Market

Cardiometabolic Diseases—Value Chain Analysis

Impact of Regulatory and Pricing Policies

VBP Models—Impact Analysis

Disruptive Market Participants

New Market Opportunities

New Market Opportunities (continued)

Merger, Acquisition, and Partnership Assessment

Merger, Acquisition, and Partnership Assessment (continued)

Market Drivers

Drivers Explained

Drivers Explained (continued)

Market Restraints

Restraints Explained

Restraints Explained (continued)

Market Summary

Methodology and Forecast Assumptions

Revenue Forecast by Segment

Revenue Forecast Discussion

Key Segment Findings

Key Segment Findings (continued)

Key Segment Findings (continued)

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Global Market Share Analysis

Competitive Landscape—Pipeline Analysis

Key Companies to Watch

Key Segment Findings

Key Segment Findings (continued)

Key Segment Findings (continued)

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Global Market Share Analysis

Competitive Landscape—Pipeline Analysis

Key Companies to Watch

Key Segment Findings

Key Segment Findings (continued)

Key Segment Findings (continued)

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Global Market Share Analysis

Competitive Landscape—Pipeline Analysis

Key Companies to Watch

Key Segment Findings

Key Segment Findings (continued)

Key Segment Findings (continued)

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Global Market Share Analysis

Competitive Landscape—Pipeline Analysis

Key Companies to Watch

Key Future Trends for Cardiometabolic Diseases Market

Transformation in Cardiometabolic Industry Ecosystem—2017

5 Major Growth Opportunities

Growth Opportunity Impact Analysis

Growth Opportunity 1—Enhanced Patient Engagement Through Digital Therapeutics

Growth Opportunity 2—Clinical Support leveraged Through AI

Growth Opportunity 3—Innovative Drug Delivery Technologies for Better Drug Efficacy

Growth Opportunity 4—Regenerative Medicine for Novel Curative Therapies

Growth Opportunity 5—Leveraging Biomarkers for Risk Assessment and Disease Diagnosis

Strategic Imperatives for Success and Growth

3 Big Predictions

Legal Disclaimer

Cardiometabolic Health Congress (CMHC)

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

Merger, Acquisition, and Partnership Assessment

Merger, Acquisition, and Partnership Assessment (continued)

Abbreviations

Market Engineering Methodology

Related Research
Globally, cardiometabolic diseases are witnessing a consistent rise in prevalence every year, with hypertension and diabetes among the leading conditions. A rising population of hypertension is, in turn, leading to growing incidence of chronic heart failure with about 26 million cases of CHF globally. Although drug therapies are the first line of treatment in cases of CHF, hypertension, and diabetes, obesity treatment requires a mixture of nutritional, behavioral, and drug therapies, wherein drugs act as an adjunct to the behavioral therapies. With the growing number of cardiometabolic cases worldwide, the market is slowly shifting toward ‘Therapy-as-a-Service’ model, with the implementation of adjunct therapies such as digital therapeutics, AI-based predictive diagnostic tools as well as nutritional and behavioral therapies alongside traditional drug treatment. This has helped establish a comprehensive care continuum across the industry, with wellness programs playing an important role in disease diagnosis, treatment, and monitoring.--BEGIN PROMO--

Research Scope

The present study aims at identifying some of the key growth opportunities, which are set to drive the market in the next few years. Additionally, the study also identifies the most prevalent and emerging business models across the market, which are supporting industry stakeholders in enhancing their geographic coverage in terms of patient outreach and address challenges of inadequate patient access. The study provides in-depth revenue and market analysis of 4 key markets, chronic heart failure (CHF), hypertension, diabetes, and obesity. The study also highlights some of the key market drivers and restraints that affect the growth. It gives an overview of the competitive environment providing brief insights on some of the game-changing participants across each segment that are working toward developing disruptive technologies and drugs, thus maintaining their growth trajectory.

More Information
No Index No
Podcast No
Author Aarti Chitale
Industries Healthcare
WIP Number MDB6-01-00-00-00
Keyword 1 Cardiometabolic
Is Prebook No
GPS Codes 9600-B1,9611-B1